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Catherine M. Bollard*, Vanderson RochaThe annual meeting in Salt Lake City marks a return of the
Tandem Meetings to an ambience of snow-capped peaks,
with the (albeit somewhat distant) prospect of skiing. The
retreat of our annual meeting to lower ground in the last
few years was a necessity driven by the continuing growth of
the meeting, reﬂecting an increasing number of active
stem cell transplantation programs, a growing international
membership, and increasing diversity in the specialties and
training of participants. Year by year, as new technologies
and new insights into transplantation biology move the ﬁeld
relentlessly forward, our meeting documents the improved
outcomes of stem cell transplantation. However, for these
improvements to translate into optimal transplantation
practice, the advances must be disseminated to the profes-
sionals delivering clinical care. We consider the annual
educational supplement a critical piece of this process.
This year’s supplement covers some new biological
insights, novel treatments, disease-speciﬁc topics, and new
understandings of some old intractable problems. Develop-
ments in leukemia biology are addressed by Scott Armstrong
and colleagues, who discuss the therapeutic targeting of
leukemia stem cells. Similarly, developments in the biology
of diffuse large B cell lymphoma are discussed by Randy
Gascoyne, Craig Moskowitz, and Thomas Shea. Of the new
treatments introduced, last year’s dramatic demonstration of
the antileukemic potency of chimeric antigen receptor
(CAR)-transformed T cell technology is covered in this
supplement by contributions from Stanley Riddell, Michael
Jensen, and Carl June. Katy Rezvani, Ronald Levy, and John
Barrett have assembled a broad review of cancer vaccines
and T cell therapy. The state of the art of gene therapy is well
summarized by Donald B. Kohn, Sung-Yun Pai, and Michel
Sadelain. Novel therapeutic advances for multiple myeloma
are also highlighted in an important discussion led by Para-
meswaran Hari. Alternative donor sources, including cord
blood, haploidentical related donors, and unrelated donors,
represent a fast-growing ﬁeld, covered here in a National
Marrow Donor Program session (Willis H. Navarro, Galen E.
Switzer, Michael Pulsipher) and by Juliet Barker, Helen
Heslop, and Marcelo Fernandez Vina. The ﬁeld of cord blood
transplantation continues to advance, not only in terms of
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is well covered by EJ Shpall, Colleen Delaney, and Catherine
Bollard.
The 2013 TandemMeetings has been intentionally biased
toward pediatric topics (in keeping also with the expertise of
the co-editors of this supplement!). Our supplement
contents reﬂect this bias, with excellent reviews of pediatric
lymphomas (Mitchell S. Cairo, Willi Woessmann, and John
Pagel), metabolic disorders (Jaap van Bolens, Paul Orchard,
and Gerald Raymond), and nonmalignant disorders
(John Tisdale, Mary Eapen, and Ricardo Saccardi). Other
topics include transplantation in unique pediatric pop-
ulations: infants, adolescents, and children with Down
syndrome.
The practice of stem cell transplantation still carries the
burden of some intractable complications, which continue to
limit a successful outcome. No educational supplement
would be complete without articles on graft-versus-host
disease (GVHD), and this year, improved diagnostic
markers for GVHD and new insights into GVHD are described
by Pavan Reddy and Amin Alousi. Novel ways to improve
immune reconstitution are addressed by Marcel van den
Brink, Crystal Mackal, Ann Leen, and colleagues. Further-
more, the problem of posttransplantation complications is
highlighted by a group of experts coordinated by Greg Yanik
and includes veno-occlusive disease, which is well discussed
by a group of experts from the Dana-Farber Cancer Center led
by Paul Richardson. Finally, statistical design and analysis is
critical for all bone marrow transplantation studies, and
novel statistical approaches for these studies are summa-
rized by Brent Logan.
Not all of us ski (Dr. Rocha, among others), and even those
who do cannot always claim to have improvedmuch over the
years. So it is gratifying that despite such lack of progress on
the slopes, our meeting and our educational supplement
continue to mark the steady advancement of our ﬁeld. This
does not come without effort, and we would like to thank all
of the authors, the associate editors, and Bob Krawisz, who
helped us put together what we believe is a comprehensive
and exciting summary of the highlights of the past year in
transplantation.
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